Literature DB >> 19637252

Women's perspectives on counseling about risks for medication-induced birth defects.

Aimee K Santucci1, Melanie A Gold, Aletha Y Akers, Sonya Borrero, Eleanor Bimla Schwarz.   

Abstract

PURPOSE: This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs).
METHODS: We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus.
RESULTS: Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP.
CONCLUSIONS: Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19637252      PMCID: PMC2806515          DOI: 10.1002/bdra.20618

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  11 in total

1.  Three approaches to qualitative content analysis.

Authors:  Hsiu-Fang Hsieh; Sarah E Shannon
Journal:  Qual Health Res       Date:  2005-11

Review 2.  Drugs in pregnancy.

Authors:  G Koren; A Pastuszak; S Ito
Journal:  N Engl J Med       Date:  1998-04-16       Impact factor: 91.245

3.  Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making.

Authors:  L Bonari; G Koren; T R Einarson; J D Jasper; A Taddio; A Einarson
Journal:  Arch Womens Ment Health       Date:  2005-06-17       Impact factor: 3.633

4.  Recommendations to improve preconception health and health care--United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care.

Authors:  Kay Johnson; Samuel F Posner; Janis Biermann; José F Cordero; Hani K Atrash; Christopher S Parker; Sheree Boulet; Michele G Curtis
Journal:  MMWR Recomm Rep       Date:  2006-04-21

5.  Documentation of contraception and pregnancy when prescribing potentially teratogenic medications for reproductive-age women.

Authors:  Eleanor Bimla Schwarz; Debbie A Postlethwaite; Yun-Yi Hung; Mary Anne Armstrong
Journal:  Ann Intern Med       Date:  2007-09-18       Impact factor: 25.391

6.  The effect of preconception counselling on lifestyle and other behaviour before and during pregnancy.

Authors:  Joyce Elsinga; Lieke C de Jong-Potjer; Karin M van der Pal-de Bruin; Saskia le Cessie; Willem J J Assendelft; Simone E Buitendijk
Journal:  Womens Health Issues       Date:  2008 Nov-Dec

7.  Prescription drug use in pregnancy.

Authors:  Susan E Andrade; Jerry H Gurwitz; Robert L Davis; K Arnold Chan; Jonathan A Finkelstein; Kris Fortman; Heather McPhillips; Marsha A Raebel; Douglas Roblin; David H Smith; Marianne Ulcickas Yood; Abraham N Morse; Richard Platt
Journal:  Am J Obstet Gynecol       Date:  2004-08       Impact factor: 8.661

8.  Pre-conception counselling in primary care: prevalence of risk factors among couples contemplating pregnancy.

Authors:  Karin M van der Pal-de Bruin; Saskia le Cessie; Joyce Elsinga; Lieke C de Jong-Potjer; Arie van Haeringen; Arie Knuistingh Neven; S Pauline Verloove-Vanhorick; Pim Assendelft
Journal:  Paediatr Perinat Epidemiol       Date:  2008-05       Impact factor: 3.980

Review 9.  Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome.

Authors:  Janine B Winterbottom; Rebecca Md Smyth; Ann Jacoby; Gus A Baker
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

10.  Computerized counseling for folate knowledge and use: a randomized controlled trial.

Authors:  Eleanor Bimla Schwarz; Mindy Sobota; Ralph Gonzales; Barbara Gerbert
Journal:  Am J Prev Med       Date:  2008-12       Impact factor: 5.043

View more
  17 in total

1.  Pilot study of reproductive health counseling in a pediatric rheumatology clinic.

Authors:  Tova Ronis; Jennifer Frankovich; Sophia Yen; Christy Sandborg; Peter Chira
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-04       Impact factor: 4.794

2.  Using the electronic medical record to refer women taking category D or X medications for teratogen and contraceptive counseling.

Authors:  Sheila K Mody; Jennifer Wu; Marla Ornelas; Colleen Kernahan; Elizabeth Salas; Kelly Kao; Robert Felix; Christina Chambers
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-06-23

3.  Promoting safe prescribing in primary care with a contraceptive vital sign: a cluster-randomized controlled trial.

Authors:  Eleanor Bimla Schwarz; Sara M Parisi; Sanithia L Williams; Grant J Shevchik; Rachel Hess
Journal:  Ann Fam Med       Date:  2012 Nov-Dec       Impact factor: 5.166

4.  Clinical decision support to promote safe prescribing to women of reproductive age: a cluster-randomized trial.

Authors:  Eleanor Bimla Schwarz; Sara M Parisi; Steven M Handler; Gideon Koren; Elan D Cohen; Grant J Shevchik; Gary S Fischer
Journal:  J Gen Intern Med       Date:  2012-07       Impact factor: 5.128

5.  Impact of physician counseling and perception of teratogenic risks: a survey of 96 nonpregnant women with anxiety.

Authors:  Tiffany Behringer; Bruce L Rollman; Bea Herbeck-Belnap; Patricia R Houck; Sati Mazumdar; Eleanor Bimla Schwarz
Journal:  Prim Care Companion CNS Disord       Date:  2011

6.  Making Decisions About Medication Use During Pregnancy: Implications for Communication Strategies.

Authors:  Molly M Lynch; Linda B Squiers; Katherine M Kosa; Suzanne Dolina; Jennifer Gard Read; Cheryl S Broussard; Meghan T Frey; Kara N Polen; Jennifer N Lind; Suzanne M Gilboa; Janis Biermann
Journal:  Matern Child Health J       Date:  2018-01

7.  Teratogenic risk perception and confidence in use of medicines in pairs of pregnant women and general practitioners based on patient information leaflets.

Authors:  Sofia Frost Widnes; Jan Schjøtt; Geir Egil Eide; Anne Gerd Granas
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

8.  Using the electronic medical record to assess contraception usage among women taking category D or X medications.

Authors:  Sheila K Mody; John Paul Farala; Jennifer Wu; Robert Felix; Christina Chambers
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2015-08-25

9.  Counseling about medication-induced birth defects with clinical decision support in primary care.

Authors:  Eleanor Bimla Schwarz; Sara M Parisi; Steven M Handler; Gideon Koren; Grant Shevchik; Gary S Fischer
Journal:  J Womens Health (Larchmt)       Date:  2013-08-09       Impact factor: 2.681

10.  Improving Safe Use of Medications During Pregnancy: The Roles of Patients, Physicians, and Pharmacists.

Authors:  Molly M Lynch; Jacqueline B Amoozegar; Emily M McClure; Linda B Squiers; Cheryl S Broussard; Jennifer N Lind; Kara N Polen; Meghan T Frey; Suzanne M Gilboa; Janis Biermann
Journal:  Qual Health Res       Date:  2017-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.